Considering alloHCT: Digital Stories for Myeloid Cancers
This study is for people with myeloid cancers (like AML, MDS, or myelofibrosis) who are considering an allogeneic hematopoietic cell transplant (alloHCT). It tests an intervention called CHORDS, which includes digital stories from people who have had alloHCT consultations, and exercises to help you think about your values and what matters most to you. This is compared to usual care. The study aims to see how many participants stay in the study and complete the activities. To join, you must be over 21, have a myeloid cancer, be considered for alloHCT, and speak English. The study is currently unclear on its status and plans to enroll 120 participants.
- Study design
- This is a pilot study that randomly assigns participants to either the CHORDS intervention or usual care. About 120 people are expected to join.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- You would be followed from enrollment up to about 2 weeks after your alloHCT office visit.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Percentage of Participants Retained (Feasibility - Retention Rate)From enrollment (Day -30 to Day 0) to 2 weeks post-alloHCT office visit (Day 9-19)
Feasibility will be assessed based on the percentage of enrolled participants who complete both the intervention and post-intervention secondary outcome assessments. The number of participants who complete all study procedures will be divided by the total number enrolled to calculate the retention rate. Higher percentages indicate greater feasibility.